Related Experiment Videos
Low-dose tacrolimus for intractable myasthenia gravis
Hiroaki Yoshikawa1, Kazunori Mabuchi, Yoshihiro Yasukawa
1Health Service Center, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa 920-1192, Japan. hiroaki@kenroku.kanazawa-u.ac.jp
Summary
Low-dose tacrolimus and prednisolone effectively treated two patients with severe myasthenia gravis (MG). This combination therapy improved muscle strength and reduced key disease markers, offering a promising treatment for difficult MG cases.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Intractable MG cases present significant treatment challenges.
- Current therapies may have limitations for severe or refractory disease.
Observation:
- Two patients with intractable myasthenia gravis were treated.
- The treatment involved a combination of low-dose tacrolimus and prednisolone.
- Clinical and immunological parameters were monitored.
Findings:
- Both patients experienced significant improvement in myasthenic symptoms.
- Serum anti-acetylcholine receptor antibody levels decreased.
- Nerve conduction studies showed reduced abnormalities (waning compound muscle action potential).
- Interleukin-2 (IL-2) production by peripheral blood mononuclear cells was suppressed.
Implications:
- Low-dose tacrolimus plus prednisolone is a potentially effective therapeutic strategy for intractable MG.
- This regimen may modulate the autoimmune response in myasthenia gravis.
- Further research is warranted to confirm efficacy and safety in a larger cohort.